Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Lidocaine 50mg/5ml (1%) inj Mini-Plasco ampoules (Hameln)
1502010J0BNAKBD
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 193 |
|
Lidocaine 100mg/10ml (1%) inj Mini-Plasco ampoules (B.Braun)
1502010J0BNAFBW
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 146 |
|
Lidocaine 100mg/5ml (2%) inj Mini-Plasco ampoules (Hameln)
1502010J0BNAICB
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 97 |
|
Lidocaine 200mg/10ml (2%) inj Mini-Plasco ampoules
1502010J0BNAACE
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 50 |
|
Lidocaine 100mg/10ml (1%) inj Mini-Plasco ampoules (Hameln)
1502010J0BNAJBW
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 48 |
|
Lidocaine 50mg/5ml (1%) inj Mini-Plasco ampoules (B.Braun)
1502010J0BNABBD
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 29 |
|
Lidocaine 200mg/20ml (1%) inj Mini-Plasco ampoules
1502010J0BNAECJ
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 16 |
|
Lidocaine 100mg/5ml (2%) inj Mini-Plasco ampoules (B.Braun)
1502010J0BNACCB
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 15 |
|
Lidocaine 400mg/20ml (2%) inj Mini-Plasco ampoules
1502010J0BNAHCU
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | 10 |
|
Lidocaine 40mg/2ml (2%) inj Mini-Plasco ampoules
1502010J0BNADBE
|
Mini-Plasco lidocaine hydrochloride | Lidocaine hydrochloride | Anaesthesia | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.